Literature DB >> 10524638

The network: a strategy to describe the relationship between quality of life and disease activity. The case of inflammatory bowel disease.

H Hjortswang1, S Almer, M Ström.   

Abstract

OBJECTIVE: Health is a complex and multi-dimensional entity and is neither easily determined nor easily conveyed to others. Publications have often combined various variables of disease activity and health-related quality of life (HRQoL), used the variables interchangeably or utilized summation indices to compare health assessment. The aim of this study is to investigate the relationship between measurements of disease activity and HRQoL. STUDY: design Cross-sectional evaluation of disease activity and HRQoL. STUDY POPULATION: Two hundred and eleven consecutive patients with ulcerative colitis.
SETTING: The catchment area of Linköping University Hospital. MEASUREMENTS: HRQoL was measured using two questionnaires, the Sickness Impact Profile (SIP) and the Rating Form of IBD Patient Concerns (RFIPC). Patients were also asked if they were 'feeling fit and well', as a measurement of general health perception. Disease activity was measured by means of symptom cards, laboratory tests and sigmoidoscopy.
RESULTS: The correlations (Spearman's r (r5)) between variables of disease activity and HRQoL were low. 'Feeling fit and well' was best correlated to worries and concerns (the RFIPC, rs 0.32, P < 0.05), while there was a decreasing association with subjective functional status (the SIP, rs 0.31, P < 0.05), symptoms (stools per day, rs 0.15, not significant) and biological variables (endoscopy score, rs 0.04, not significant).
CONCLUSION: The correlations between traditional measurements of disease activity and various measures of HRQoL are low. We therefore propose a system whereby the process is conceptualized using a 'network strategy', ordering the measurements of disease activity and HRQoL into five dimensions: biological variables, symptoms, functional status, worries and concerns, and health perceptions. We feel that this method of interpretation more accurately reflects the overall health of a group of patients with IBD than more traditional summation indices.

Entities:  

Mesh:

Year:  1999        PMID: 10524638

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  5 in total

1.  Development of a culturally appropriate health-related quality of life measure for human immunodeficiency virus-infected children in Thailand.

Authors:  Warunee Punpanich; Ron D Hays; Roger Detels; Kulkanya Chokephaibulkit; Umaporn Chantbuddhiwet; Pimsiri Leowsrisook; Wasana Prasitsuebsai
Journal:  J Paediatr Child Health       Date:  2010-10-26       Impact factor: 1.954

2.  Patient-perceived usefulness of online electronic medical records: employing grounded theory in the development of information and communication technologies for use by patients living with chronic illness.

Authors:  Warren J Winkelman; Kevin J Leonard; Peter G Rossos
Journal:  J Am Med Inform Assoc       Date:  2005-01-31       Impact factor: 4.497

3.  Assessing health status in inflammatory bowel disease using a novel single-item numeric rating scale.

Authors:  Bijal Surti; Brennan Spiegel; Andrew Ippoliti; Eric A Vasiliauskas; Peter Simpson; David Q Shih; Stephan R Targan; Dermot P B McGovern; Gil Y Melmed
Journal:  Dig Dis Sci       Date:  2012-12-19       Impact factor: 3.199

4.  The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients.

Authors:  Guillermo Bastida; Pilar Nos; Mariam Aguas; Belén Beltrán; Marisa Iborra; Vicente Ortiz; Vicente Garrigues; Rafael Estevan; Julio Ponce
Journal:  BMC Gastroenterol       Date:  2010-03-02       Impact factor: 3.067

5.  Factor structures of the Swedish Version of the RFIPC: Investigating the Validity of Measurements of IBD Patients' Worries and Concerns.

Authors:  Susanna Jaghult; Fredrik Saboonchi; Unn-Britt Johansson; Regina Wredling; Marjo Kapraali
Journal:  Gastroenterology Res       Date:  2010-09-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.